KMID : 1225720190110050677
|
|
Allergy, Asthma & Immunology Research : AAIR 2019 Volume.11 No. 5 p.677 ~ p.690
|
|
Activated Leukocyte Cell Adhesion Molecule Modulates Th2 Immune Response in Atopic Dermatitis
|
|
Oh Mi-Seon
Hong Jung-Yeon Kim Mi-Na Kwak Eun-Ji Kim Soo-Yeon Kim Eun-Gyul Lee Kyung-Eun Kim Yun-Seon Jee Hye-Mi Kim Seo-Hyeong Sol In-Suk Park Chang-Ook Kim Kyung-Won Sohn Myung-Hyun
|
|
Abstract
|
|
|
Purpose: Activated leukocyte cell adhesion molecule (ALCAM), a member of the immunoglobulin superfamily, is highly expressed on dendritic cells. ALCAM and its receptor CD6 are co-stimulatory molecules in the immunological synapse; their interaction is required for T cell activation. While atopic dermatitis (AD) is recognized as a T helper 2 (Th2)-mediated allergic disease, the role of ALCAM in its pathogenesis is unclear.
Methods: ALCAM levels were measured in the serum of AD patients and AD-induced murine model by ovalbumin treatment. We next investigated transepidermal water loss, clinical score, Th2-immune responses, skin barrier gene expression and T-cell activation using wild-type (WT) and ALCAM deficiency mice. An oxazolone-induced AD-like model was also established and analyzed using WT- and ALCAM-deficient mice.
Results: We found that serum ALCAM levels were elevated in pediatric AD patients as well as WT AD mice, whereas Th2-type cytokine production and AD symptoms were suppressed in ALCAM-deficient mice. In addition, CD4+ effector T-cell counts in murine skin and skin-draining lymph nodes were lower in ALCAM-deficient mice than in their WT counterparts. ALCAM deficiency was also linked to higher expression of skin barrier genes and number of lamellar bodies.
Conclusions: These findings indicate that ALCAM may contribute to AD pathogenesis by meditating a Th2-dominant immune response and disrupting the barrier function of the skin.
|
|
KEYWORD
|
|
ALCAM, CD166, atopic dermatitis, type 2 helper T cells, skin barrier
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|